Switch to:
More From Other Websites
Will Mylan, Glaukos, Supernus Live Up To Q4 Growth Views Next Week? Feb 24 2017
Mylan (MYL) to Post Q4 Earnings: Will the Stock Disappoint? Feb 24 2017
Goldman Says Buy Health-Care, Retail Volatility Before Trump Address Feb 22 2017
Where Are the Best Buying Opportunities in Stocks Right Now? Feb 21 2017
Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug Feb 21 2017
Mylan's Proposed Biosimailar for Cancer Under Review in U.S. Feb 17 2017
Blog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar -... Feb 17 2017
Trump's pick to lead health agency calls EpiPen issue 'disturbing' Feb 16 2017
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar... Feb 16 2017
Health Care Sector Led the S&P 500’s Rally on February 15 Feb 16 2017
Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC Feb 15 2017
Tepper's Appaloosa triples stake in Allergan Feb 15 2017
David Tepper Increases Wagers on Drug Companies Feb 14 2017
Mylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible... Feb 14 2017
Mylan Shares Unchanged as Kaleo Releases EpiPen Competitor Feb 14 2017
Company announces pause for drug after price criticism Feb 13 2017
Company announces pause for drug after price criticism Feb 13 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK